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ABSTRACT: The search for synthetic selective compounds
for G-protein-coupled receptors has provided a myriad of
molecules with high selectivity and therapeutic potential. In
some cases, however, selectivity is difficult to obtain. For
instance, the selectivity ratio is relatively low for compounds
acting on D2 and D3 dopamine receptors, which are targets of
neurodegenerative diseases such as Parkinson’s and Hunting-
ton’s. From a therapeutic point of view, it is of interest the
relative recent discovery of biased agonism, which is
characterized by different signaling pathways engaged by
different compounds acting on a given receptor. The aim of
this paper was to investigate whether new piribedil-derived
compounds could display higher selectivity for D2 or D3
receptor and/or provide biased signaling. The results show that selectivity was not different, but that one of the molecules
described here, 5-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)quinolin-8-ol (10), does engage Gi-mediated signaling via D2 or
D3 receptors, whereas it does not activate the mitogen-activated-protein kinase pathway, which is usually activated by dopamine
receptor agonists.
1. INTRODUCTION
Dopamine is one of the main neurotransmitters in the central
nervous system (CNS), exerting its functions via five different
receptors, D1 to D5, that are expressed in different neuronal
types and in different regions of the brain. They all belong to
the superfamily of G-protein-coupled receptors and are
subdivided into D1-like (D1 and D5), which are coupled to
Gs and their activation leads to activation of adenylyl cyclase,
and D2-like (D2, D3 and D4), which are coupled to Gi. Apart
from mediating changes in one of the main intracellular second
messengers, adenosine 3′:5′-cyclic phosphate (cAMP), they
also engage the mitogen-activated-protein kinase (MAPK)
pathway. Dopamine receptors are targets of a variety of
neurological and neuropsychiatric diseases. First of all, agonists
of dopamine receptors are used in Parkinson’s disease (PD),
which consists of denervation of striatal fibers projecting from
the substantia nigra.1 As an example, pramipexole is a non-
ergot dopamine receptor agonist used in the therapy of PD and
also of the restless legs syndrome.2−4
The piperazinyl pyrimidine (I, Figure 1) is a privileged motif
present in a number of therapeutic agents showing anti-
neuroinflammatory activity, such as compound GIBH-130,
able to suppress the IL-1β in LPS-activated microglia,
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trials;5 MW01-070C, a novel anti-neuroinflammatory agent;6
Minozac, a drug under development as a water-soluble oral
drug candidate for Alzheimer’s disease;7 MW01-5-188WH, a
new molecule that selectively inhibits glial activation in the
CNS,8 or piribedil (Figure 1), an agent used for treating early
and advanced PD that blocks α2-adrenoreceptors with minor
effects on serotoninergic, cholinergic, and histaminergic
receptors.9−11 Furthermore, and of interest for the present
work, piribedil is a dopamine receptor agonist that also has
potential in the therapy of PD.12−14 However, piribedil taken
by patients leads to side effects,15 thus limiting its therapeutic
potential. Piribedil is a mixed D2/D3 compound. It should be
noted that D3 compounds have potential to combat some of
the side effects of dopamine-based therapies in PD, namely
dyskinesia, which correlates with increases in the expression
levels of the D3 receptor.
16,17 Piribedil may therefore be a lead
compound for development of D3 receptor-selective com-
pounds, as well as for gaining a better understanding of the
function differences between D2 and D3 receptors.
With these ideas in mind, and continuing with our program
on the synthesis and biological evaluation of N-arylpiperazine
derivatives,18,19 we have designed N-aryl analogues of piribedil,
in which we have also substituted the 5-methylbenzo[d][1,3]-
dioxole motif by the 5-methylquinolin-8-ol group, resulting in
5-((arylpiperazin-1-yl)methyl)quinolin-8-ol type of com-
pounds 1−11 (Figure 1), incorporating a diverse array of
electron-donating or electron-withdrawing substituents at
different positions in the aryl ring. These modifications should
have positive consequences because of the biological and
physicochemical properties that the 8-hydroxyquinoline group
underscored by drugs bearing this structural motif.20,21 As a
result from these studies, we have identified 5-((4-(pyrimidin-
2-yl)piperazin-1-yl)methyl)quinolin-8-ol (10) (Figure 1) as a
compound that exerts a profound bias in dopamine receptor
signaling.
2. RESULTS AND DISCUSSION
2.1. Chemistry. The 5-((4-phenylpiperazin-1-yl)methyl)-
8-hydroxyquinoline derivatives 1, 2, 3,22 4−6, 7,23 8, 9,23 10,
and 11 were synthesized in a “one-pot reaction”, by
condensation of a solution of 5-(chloromethyl)-8-hydroxyqui-
noline hydrochloride24 [or 2-(bromomethyl)-1,4-dimethoxy-
benzene18 in the case of compound 1] with the appropriate
commercially available piperazine, in EtOH/tetrahydrofuran
(THF) (1/1), during 15 min, at reflux. All compounds showed
good analytical data in excellent agreement with their structure
or the data described in the literature.
Inspection of the pharmacological data available for
compounds 1−11 on public sources25 revealed that, apart
from piribedil, data are known only for 5-((4-phenylpiperazin-
1-yl)methyl)quinolin-8-ol (9) (ChEMBL 1457644). Com-
pound 9 was tested on a total of 52 assays for which IC50 and
EC50 data were measured for 6 and 12 of them, respectively.
Among them, of mention is the measured EC50 value of 3763
nM (pEC50 of 5.42) for streptokinase A. However, most
surprisingly, even though molecule 9 shows close resemblance
to piribedil and contains a phenyl piperazinyl moiety, a known
privileged motif among dopamine active ligands, it was not
tested on any G protein-couple receptor.
2.2. Biological Activity. The effect of the compounds
synthesized on the D2 and D3 receptors was first tested in
cAMP determination assays. As both D2 and D3 receptors are
coupled to Gi, agonists lead to inhibition of the adenylyl
cyclase. A total of 11 compounds at concentrations 200 nM
and 1000 nM were tested in D2- or D3-receptor-expressing
cells treated with forskolin, which leads to increases in cAMP.
Any agonistic receptor-mediated effect will lead to a significant
reduction in forskolin-induced cAMP levels. On the basis of
this first (see Figure 2) screening, products 5, 6, 9, and 10 were
selected for further studies. Dose-responses curves for cAMP
and pERK1/2 assays are shown in Figure 3 in which it is
shown that piribedil was the most potent compound.
Raclopride, a nonselective D2/D3 receptor antagonist, was
Figure 1. General structure of the piperazinyl pyrimidine motif (I), piribedil, and the 5-((arylpiperazin-1-yl)methyl)quinolin-8-ols 1−11.
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able to revert the effect of piribedil and piribedil-related
compounds (Figure 4). Furthermore, non-transfected cells did
not respond to the dopamine receptor agonists (Figure S1).
For those selected compounds and for piribedil, dose−
response effects were measured (Figure 3). This approach was
performed in cAMP determination and ERK1/2 phosphor-
ylation assays in both D2- and D3-receptor-expressing cells.
IC50 or EC50 values and the percentage of response were
calculated using sumanirole (100 nM) as selective D2-receptor
or 7-OH-PIPAT (100 nM) as selective D3-receptor agonists.
The results are summarized in Table 1 which presents IC50 or
EC50 values plus the percentage of effect respect to a reference
compound. As shown in Figure 4, the effect of compounds on
either D2- or D3-receptor-expressing cells was blocked by 1 μM
raclopride, a potent nonselective D2/D3 receptor antagonist.
The results confirm that, in cAMP determination assays,
piribedil is a preferential D3 compound by 2 orders of
magnitude.11 However, a recent analysis of pharmacology data
available for various compounds deposited in the ChEMBL
database25 revealed a fairly large data heterogeneity depending
on the assay type and bioactivity endpoints.26 Accordingly, we
observed that piribedil selectivity for D3 is lost when data on
MAPK assays are considered. Interestingly, this loss of
selectivity is very much in agreement with the known binding
data available in public sources,27 where the pKi of piribedil for
the D2 and D3 receptors is 6.85 and 6.60, respectively, albeit
there is a difference of 3 orders of magnitude between binding
pKi data and our MAPK pEC50 data. In contrast, the results for
the compounds synthesized in this work prove that none
displayed a clearly marked selectivity for any of the two
receptors. Remarkably, the potency of the majority of the
compounds was fairly high. However, the most salient finding
was the differential effect when, compound by compound,
cAMP and MAPK results were compared. Apart from the
disappearance of the selectivity mentioned above of piribedil
when comparing the EC50 values in ERK1/2 phosphorylation
assays, compound 10 showed a significant effect in cAMP
assays but negligible capacity of activating the MAPK pathway.
Figure 2. Signaling in HEK-293T cells expressing D2R or D3R. HEK-
293T cells transfected with cDNA encoding for D2R (A) or D3R (B)
were treated with compounds 1−11 (200 nM in white bars and 1000
nM in gray bars). cAMP accumulation was detected by time-resolved
fluorescence energy transfer (TR-FRET) in the presence of 0.5 μM
forskolin. cAMP production is expressed as % of levels obtained by
using 0.5 μM forskolin. Data are mean ± standard error of the mean
(SEM) of three different experiments in triplicates.
Figure 3. Dose response curves in HEK-293T cells expressing D2R or D3R. HEK-293T cells transfected with cDNA encoding for D2R (A) or D3R
(B) were treated with piribedil (red) or compounds 5 (orange), 6 (green), 9 (blue), or 10 (purple). cAMP accumulation was detected by TR-
FRET in the presence of 0.5 μM forskolin. cAMP production is expressed as percentage of levels obtained by using 0.5 μM forskolin. pERK1/2
phosphorylation is expressed as percentage over basal levels (100%). See General Methods for experimental details. Data are the mean ± SEM of
five different experiments in triplicates. The concentration range was 0.2−5000 nM for piribedil and 2−3000 nM for the rest of compounds.
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Therefore, molecule 10 disclosed a biased signaling in both D2
and D3 receptors.
This is important, as novel drug discovery approaches
include allosteric modulators and biased agonists.
3. CONCLUSIONS
To sum up, in this report, we have described the design,
synthesis, and biological evaluation on D2 or D3 receptors of
new piribedil derivatives. Our results show that the synthesized
compounds bind to the orthosteric center and not to any
allosteric site. Remarkably, molecule 10 shows a marked biased
agonism in both D2 and D3 receptors. Whereas variation in
intracellular cAMP levels is surely due to engagement of Gi,
ERK phosphorylation likely results from G-protein-independ-
ent signaling. Activation of G proteins involves large-scale
movements of the α-helical domain of the α-subunit of the
heterotrimeric G protein; the movement is necessary for GDP
dissociation.28−31 This mechanism of G protein activation
occurs for products 5, 6, 9, and 10 when they bind to and
activate D2R or D3R (Table 1). The marked bias of piperazine
10 with absolute lack of action on the MAPK pathway is a
most interesting, but unexpected result. Therefore, agent 10
can be considered a new tool compound to study the
mechanisms of functional selectivity between D2 and D3
dopamine receptors, which are still poorly understood.
4. EXPERIMENTAL SECTION
4.1. Chemistry. Synthesis of Compounds 1−11.
4.1.1. General Methods. Melting points were determined in
a Koffler apparatus and are uncorrected. 1H NMR and 13C
NMR spectra were recorded at room temperature in CDCl3 or
DMSO-d6 at 400 MHz and at 100.6 MHz, respectively, using
solvent peaks [CDCl3: 7.26 (D), 77.2 (C) ppm and DMSO-d6
2.50 (D) and 39.7 (C) ppm] as internal references. The
assignment of chemical shifts is based on standard NMR
experiments (1H, 13C, 1H−1H COSY, 1H−13C HSQC,
HMBC). Mass spectra were recorded on a gas chromatog-
raphy/mass spectrometry (MS) spectrometer with an API-ES
ionization source. Elemental analyses were performed at the
IQOG (CSIC, Spain). Thin-layer chromatography analyses
Figure 4. Reversion of agonist effect by raclopride in HEK-293T cells expressing D2R or D3R. HEK-293T cells transfected with cDNA encoding for
D2R (A, C) or D3R (B, D) were pretreated with a dopamine receptor antagonist (1 μM raclopride) and subsequently treated with piribedil or
compounds 6 and 10 (300 nM). cAMP accumulation was detected by TR-FRET in the presence of 0.5 μM forskolin. cAMP production is
expressed as % of levels obtained by using 0.5 μM forskolin. Data are the mean ± SEM of three different experiments in triplicates. One-way
ANOVA followed by Bonferroni’s multiple comparison post-hoc test were used for statistical analysis. (*p < 0.05, **p < 0.01, ***p < 0.001; vs
treatment with forskolin); (#p < 0.05, ###p < 0.001; vs treatment with agonist).
Table 1. IC50 (cAMP Assays), EC50 (pERK1/2 MAPK Assays), and Percentage Values Versus Effect of 100 nM Sumanirole
(D2R) or 100 nM 7-OH-PIPAT (D3R) of Piribedil and Compounds 5, 6, 9, and 10
a
HEK-D2R reference: 100 nM sumanirole HEK-D3R reference: 100 nM 7-OH-PIPAT
compound cAMP pIC50 ± SD MAPK pEC50 ± SD cAMP pIC50 ± SD MAPK pEC50 ± SD
piribedil 7.5 ± 0.5 9.5 ± 0.4 9.6 ± 0.6 9.5 ± 0.9
167% 131% 118% 179%
5 6.1 ± 0.4 7.4 ± 0.9 6.4 ± 0.7 no effect
129% 47% 105%
6 6.2 ± 0.5 6.7 ± 0.4 7.7 ± 0.5 6.3 ± 1.3
103% 75% 94% 50%
9 6.7 ± 0.4 7.3 ± 0.7 6.2 ± 0.4 6.6 ± 0.4
88% 45% 125% 54%
10 6.5 ± 0.6 no significant effect 6.7 ± 0.5 no significant effect
93% 118%
aPercentages respect the effect of D2 or D3 receptor reference compounds were calculated using the maximal effect obtained after data fitting.
Compounds 5 and 10 did not led to any significant ERK1/2 phosphorylation.
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were performed on silica F254 and detection by UV light at
254 nm. Column chromatography was performed on silica gel
60 (230 mesh) (Scheme 1).
4.1.2. Synthesis of 5-((Arylpiperazin-1-yl)methyl)quinolin-
8-ol Derivatives. To a solution of 1-arylpiperazine derivatives
(0.1 mmol) in EtOH/THF (5/5 mL, v/v), TEA (three drops)
and 5-(chloromethyl)quinolin-8-ol hydrochloride30 (0.1
mmol) were added. The reaction was refluxed for the indicated
time in each case. The solvent was evaporated, and the crude
was diluted with CH2Cl2, washed with water, and extracted
with CH2Cl2. The organic layer was dried with sodium sulfate
and concentrated. Recrystallization in ethanol afforded the
corresponding products as pure white solids (Scheme 2).
4.1.3. 1-(2,5-Dimethoxybenzyl)piperazine.32 To a solution
of piperazine (0.516 g, 6 mmol) in dry THF (5 mL), a solution
of 2-(bromomethyl)-1,4-dimethoxybenzene18 (0.231 g, 1
mmol) in THF (2 mL) was added dropwise. The reaction
was refluxed for 30 min. Then, the reaction was diluted with
EtOAc, washed with water, and extracted with EtOAc. The
organic layer was dried with sodium sulfate, and the solvent
was evaporated to afford a white sol id 1-(2,5-
dimethoxybenzyl)piperazine22 (0.242 g, 99%); Rf = 0.1
(hexane/EtOAct, 1/1, v/v); IR (KBr) ν: 3002, 2948, 2832,
1497 cm−1; 1H NMR (400 MHz, CDCl3): δ 6.97 (dd, J = 3.0,
0.4 Hz, 1H), 6.77 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 3.76 (s,
3H, OMe), 3.76 (s, 3H, OMe), 3.51 (s, 2H, CH2), 2.89 (t, J =
4.9 Hz, 4H, 2× CH2), 2.47 (s, 4H, 2CH2), 2.24 (s, 1H, NH);
13C NMR (101 MHz, CDCl3): δ 153.4, 152.0, 127.3, 116.3,
112.0, 111.5, 56.5, 56.1, 55.6, 54.2, 46.0; MS (EI+, m/z): 236.3
[M]+, 194.02, 151.1.
4.1.4. 5-((4-(2,5-Dimethoxybenzyl)piperazin-1-yl)methyl)-
quinolin-8-ol (1). (0.217 g, 67%); Rf = 0.3 (dichloromethane/
methanol, 10/1); mp 145−6 °C; IR (KBr) ν: 3331, 3021,
2798, 2657, 1580, 1511 cm−1; 1H NMR (400 MHz, CDCl3): δ
8.75 (dd, J = 4.2, 1.6 Hz, 1H), 8.65 (dd, J = 8.5, 1.6 Hz, 1H),
7.43 (dd, J = 8.5, 4.2 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.05
(d, J = 7.7 Hz, 1H), 6.95 (d, J = 2.9 Hz, 1H), 6.73 (dt, J = 8.8,
5.9 Hz, 2H), 3.77 (s, 2H), 3.75 (s, 3H), 3.73 (s, 3H), 3.52 (s,
2H), 2.48 (s, 7H); 13C NMR (101 MHz, CDCl3): δ 153.3,
151.9, 151.6, 147.4, 138.5, 134.1, 128.7, 127.8, 127.4, 124.7,
121.3, 116.3, 112.0, 111.4, 108.5, 60.5, 56.0, 55.8, 55.6, 53.1,
53.0; MS (ESI+, m/z): 394.2 [M + H]+. Anal. Calcd for
C23H27N3O3: C, 70.21; H, 6.92; N, 10.68. Found: C, 70.44; H,
7.01; N, 10.77.
4.1.5. 5-((4-(4-Methoxyphenyl)piperazin-1-yl)methyl)-
quinolin-8-ol (2). (Reaction time: 15 min; 0.320 g, 92%); Rf
= 0.5 (dichloromethane/methanol, 10/1); IR (KBr) ν: 3315,
2935, 2817, 2763, 1875, 1581, 1509, 1484 cm−1; mp 173−4
°C; 1H NMR (400 MHz, CDCl3): δ 8.77 (dd, J = 4.2, 1.5 Hz,
1H), 8.69 (dd, J = 8.5, 1.5 Hz, 1H), 7.45 (dd, J = 8.5, 4.2 Hz,
1H), 7.35 (d, J = 7.7 Hz, 1H), 7.08 (d, J = 7.7 Hz, 1H), 6.90−
6.77 (m, 4H), 3.84 (s, 2H, CH2), 3.74 (s, 3H, OCH3), 3.07−
3.00 (m, 4H, 2× CH2, piperazine), 2.67−2.57 (m, 4H, 2×
CH2, piperazine);
13C NMR (101 MHz, CDCl3): δ 148.9,
147.0, 142.8, 140.9, 133.9, 129.4, 124.2, 123.1, 119.7, 116.6,
113.3, 109.5, 103.9, 55.9 (CH2), 50.7 (OCH3), 48.4 (2× CH2,
piperazine), 45.9 (2× CH2, piperazine); MS (ESI
+, m/z):
350.19 [M + H]+. Anal. Calcd for C21H23N3O2: C, 72.18; H,
6.63; N, 12.03. Found: C, 72.01; H, 6.53; N, 11.89.
4.1.6. 5-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-
quinolin-8-ol (3).22 (Reaction time: 15 min; 0.340 g, 96%);
Rf = 0.7 (dichloromethane/methanol, 10/1); mp 191−2 °C;
IR (KBr) ν: 3304, 2825, 2773, 1865, 1596, 1579, 1498, 1480
cm−1; 1H NMR (400 MHz, CDCl3): δ 8.77 (dd, J = 4.2, 1.5
Hz, 1H), 8.68 (dd, J = 8.5, 1.6 Hz, 1H), 7.45 (dd, J = 8.6, 4.2
Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.19−7.12 (m, 2H), 7.07
(d, J = 7.7 Hz, 1H), 6.88−6.75 (m, 2H), 3.84 (s, 2H, CH2),
3.20−3.01 (m, 4H, 2× CH2, piperazine), 2.70−2.50 (m, 4H,
2× CH2, piperazine);
13C NMR (101 MHz, CDCl3): δ 151.8,
149.9, 147.5, 138.6, 134.1, 129.0, 128.8, 127.8, 124.3, 124.2,
121.4, 117.1, 108.6, 60.6 (CH2), 52.8 (2× CH2, piperazine),
49.1 (2× CH2, piperazine); MS (ESI
+, m/z): 354.13 [M +
H]+, 197.08, 158.07. Anal. Calcd for C20H20ClN3O: C, 67.89;
H, 5.70; N, 11.88. Found: C, 67.72; H, 5.88; N, 12.01.
4.1.7. 5-((4-(4-(Trifluoromethyl)phenyl)piperazin-1-yl)-
methyl)quinolin-8-ol (2i = 4). (Reaction time: 15 min;
0.363 g, 94%); Rf = 0.6 (dichloromethane/methanol, 10/1);
mp 163−4 °C; IR (KBr) ν: 3317, 2820, 2771, 1897, 1616,
1578, 1508 cm−1; 1H NMR (400 MHz, CDCl3): δ 8.79 (dd, J
= 4.2, 1.6 Hz, 1H), 8.70 (dd, J = 8.6, 1.6 Hz, 1H), 7.50−7.43
(m, 3H), 7.36 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 7.7 Hz, 1H),
6.89 (d, J = 8.7 Hz, 2H), 3.86 (s, 2H), 3.30−3.14 (m, 4H),
2.65−2.56 (m, 4H); 13C NMR (101 MHz, CDCl3): δ 153.2,
151.9, 147.6, 138.7, 134.1, 129.1, 127.8, 126.4, 126.3, 126.3,
126.3, 126.1, 124.1, 123.4, 121.5, 120.5, 120.1, 114.4, 108.6,
60.7 (CH2), 52.7(2× CH2, piperazine), 48.0 (2× CH2,
piperazine); MS (ESI+, m/z): 387.89 [M + H]+, 231.16,
157.82. Anal. Calcd for C21H20F3N3O: C, 65.11; H, 5.20; N,
10.85. Found: C, 65.32; H, 5.09; N, 10.77.
4.1.8. 5-((4-(4-Fluorophenyl)piperazin-1-yl)methyl)-
quinolin-8-ol (5). (Reaction time: 15 min; 0.302 g, 82%); Rf
= 0.8 (dichloromethane/methanol, 10/1); mp 175−7 °C; IR
(KBr) ν: 3297, 2938, 2821, 1869, 1580, 1505, 1477 cm−1; 1H
NMR (400 MHz, CDCl3): δ 8.79 (d, J = 3.5 Hz, 1H), 8.70 (d,
J = 8.5 Hz, 1H), 7.47 (dd, J = 8.5, 4.1 Hz, 1H), 7.36 (d, J = 7.7
Hz, 1H), 7.09 (d, J = 7.7 Hz, 1H), 6.94 (dd, J = 11.9, 5.3 Hz,
2H), 6.89−6.79 (m, 2H), 3.86 (s, 2H), 3.13−3.02 (m, 4H),
2.68−2.55 (m, 4H); 13C NMR (101 MHz, CDCl3); δ 158.2,
155.9, 151.9, 148.0, 148.0, 147.6, 138.7, 134.1, 129.0, 127.9,
Scheme 1. Synthesis of 5-((Arylpiperazin-1-
yl)methyl)quinolin-8-ol Derivatives 1−9 and 11
Scheme 2. Synthesis of 1-(2,5-Dimethoxybenzyl)piperazine
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124.3, 121.4, 117.7, 117.7, 115.5, 115.3, 108.6, 60.6 (CH2),
53.0 (2× CH2, piperazine), 50.18 (2× CH2, piperazine); MS
(ESI+, m/z): 338.21 [M + H]+, 180.95, 158.06. Anal. Calcd for
C20H20FN3O: C, 71.20; H, 5.98; N, 12.45. Found: C, 71.33; H,
5.77; N, 12.26.
4.1.9. 5-((4-(4-Nitrophenyl)piperazin-1-yl)methyl)-
quinolin-8-ol (6). (Reaction time: 30 min; 0.320 g, 88%); Rf
= 0.6 (dichloromethane/methanol, 10/1); mp 194−5 °C; IR
(KBr) ν: 3392, 3006, 2934, 2833, 1837, 1587, 1503, 1459
cm−1; 1H NMR (400 MHz, CDCl3): δ 8.78 (d, J = 4.1 Hz,
1H), 8.68−8.63 (m, 1H), 8.12−8.06 (m, 2H), 7.46 (dd, J =
8.5, 4.2 Hz, 1H), 7.34 (d, J = 7.7 Hz, 1H), 7.08 (d, J = 7.7 Hz,
1H), 6.78 (t, J = 6.4 Hz, 2H), 3.85 (s, 2H, CH2), 3.40−3.32
(m, 4H, 2× CH2, piperazine), 2.63−2.55 (m, 4H, 2× CH2,
piperazine); 13C NMR (101 MHz, CDCl3): δ 154.8, 152.0,
147.6, 138.6, 138.2, 134.0, 129.1, 127.8, 125.9, 123.8, 121.5,
112.5, 108.6, 60.5 (CH2), 52.4 (2× CH2, piperazine), 47.0 (2×
CH2, piperazine); MS (ESI
+, m/z): 365.14 [M + H]+, 158.07.
Anal. Calcd for C20H20N4O3: C, 65.92; H, 5.53; N, 15.38.
Found: C, 65.71; H, 5.67; N, 15.44.
4.1.10. 5-((4-(2-Fluorophenyl)piperazin-1-yl)methyl)-
quinolin-8-ol (7).23 (Reaction time: 15 min; 0.330 g, 98%);
Rf = 0.6 (dichloromethane/methanol, 10/1); mp 186−8 °C;
IR (KBr) ν: 3307, 2935, 2812, 1863, 1610, 1578, 1505, 1477
cm−1; 1H NMR (400 MHz, CDCl3): δ 8.78 (dd, J = 4.2, 1.5
Hz, 1H), 8.75−8.60 (m, 1H), 7.46 (dd, J = 8.5, 4.2 Hz, 1H),
7.36 (d, J = 7.7 Hz, 1H), 7.08 (d, J = 7.7 Hz, 1H), 7.05−6.99
(m, 2H), 6.98−6.86 (m, 2H), 3.86 (s, 2H), 3.04 (d, J = 4.2 Hz,
4H), 2.70−2.58 (m, 4H); 13C NMR (101 MHz, CDCl3): δ
156.9, 154.4, 151.8, 147.5, 140.1, 140.1, 138.6, 134.1, 129.0,
127.9, 124.4, 124.4, 124.3, 122.3, 122.2, 121.34, 118.8, 118.8,
116.1, 115.9, 108.7, 60.6 (CH2), 53.1 (2× CH2, piperazine),
50.5 (CH2, piperazine), 50.5 (CH2, piperazine); MS (ESI
+, m/
z): 338.21 [M + H]+, 181.01, 158.13. Anal. Calcd for
C20H20FN3O: C, 71.20; H, 5.98; N, 12.45. Found: C, 71.09;
H, 5.71; N, 12.63.
4.1.11. 5-((4-(p-Tolyl)piperazin-1-yl)methyl)quinolin-8-ol
(8). (Reaction time: 15 min; 0.369 g, 98%); Rf = 0.5
(dichloromethane/methanol, 10/1); mp 167−8 °C; IR (KBr)
ν: 3313, 2820, 2762, 1611, 1581, 1509, 1483 cm−1; 1H NMR
(400 MHz, CDCl3): δ 8.78 (dd, J = 4.2, 1.5 Hz, 1H, CH-2),
8.71 (dd, J = 8.6, 1.5 Hz, 1H, CH-4), 7.47 (dd, J = 8.6, 4.2 Hz,
1H, CH-3), 7.37 (d, J = 7.7 Hz, 1H), 7.07 (dd, J = 14.0, 8.1
Hz, 3H), 6.82 (d, J = 8.6 Hz, 2H), 3.86 (s, 2H, CH2), 3.17−
2.96 (m, 4H, 2× CH2, piperazine), 2.70−2.56 (m, 4H, 2×
CH2, piperazine), 2.26 (s, 3H, CH3);
13C NMR (101 MHz,
CDCl3): δ 151.8, 149.2, 147.6, 138.7, 134.1, 129.6, 129.1,
129.0, 127.9, 121.5, 116.4, 108.6, 60.7(CH2), 53.1 (2× CH2,
piperazine), 49.7 (2× CH2, piperazine), 20.4 (CH3); MS
(ESI+, m/z): 334.24 [M + H]+, 177.17, 158.17. Anal. Calcd for
C21H23N3O: C, 75.65; H, 6.95; N, 12.60. Found: C, 75.82; H,
6.75; N, 12.39.
4.1.12. 5-((4-Phenylpiperazin-1-yl)methyl)quinolin-8-ol
(9).23 (Reaction time: 25 min; 0.430 g, 98%); Rf = 0.8
(dichloromethane/methanol, 10/1); mp 189−190 °C; IR
(KBr) ν: 3312, 2816, 1599, 1578, 1505, 1493, 1478 cm−1; 1H
NMR (400 MHz, CDCl3): δ 8.80 (d, J = 4.2 Hz, 1H, CH-2),
8.72 (dd, J = 8.6, 1.3 Hz, 1H, CH-4), 7.48 (ddd, J = 8.5, 4.2,
0.6 Hz, 1H, CH-3), 7.38 (d, J = 7.7 Hz, 1H), 7.30−7.21 (m,
1H), 7.10 (d, J = 7.7 Hz, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.85
(td, J = 7.7, 0.6 Hz, 1H), 3.87 (s, 2H, CH2), 3.20−3.13 (m,
4H, 2CH2, piperazine), 2.69−2.59 (m, 4H, 2CH2, piperazine);
13C NMR (101 MHz, CDCl3): δ 147.0, 146.5, 142.8, 133.9,
129.4, 124.3, 124.2, 123.1, 119.6, 116.6, 114.8, 111.2, 103.8,
55.9 (CH2), 48.2 (2× CH2, piperazine), 44.4 (2× CH2,
piperazine); MS (ESI+, m/z): 320.19 [M + H]+, 161.08,
157.76. Anal. Calcd for C20H21N3O: C, 75.21; H, 6.63; N,
13.16. Found: C, 75.42; H, 6.83; N, 13.09.
4.1.13. 5-((4-(Pyrimidin-2-yl)piperazin-1-yl)methyl)-
quinolin-8-ol (10). Prepared form 5-(chloromethyl)quinolin-
8-ol hydrogen chloride,24 and 2-(piperazin-1-yl)pyrimidine
(reaction time: 30 min; 0.307 g, 96%); Rf = 0.7 (dichloro-
methane/methanol, 10/1); mp 143−5 °C; IR (KBr) ν: 3342,
2811, 1593, 1542, 1500, 1475 cm−1; 1H NMR (400 MHz,
DMSO-d6): δ 8.78 (dd, J = 4.2, 1.5 Hz, 1H), 8.70 (dd, J = 8.5,
1.5 Hz, 1H), 8.27 (dd, J = 4.7, 0.6 Hz, 2H), 7.46 (dd, J = 8.5,
4.2 Hz, 1H), 7.33 (d, J = 7.7 Hz, 1H), 7.07 (d, J = 7.7 Hz, 1H),
6.45 (t, J = 4.7 Hz, 1H), 3.81 (s, 2H, CH2), 3.78−3.73 (m, 4H,
2× CH2, piperazine), 2.56−2.43 (m, 4H, 2× CH2, piperazine);
13C NMR (101 MHz, DMSO-d6): δ 161.5, 157.7, 151.8, 147.5,
138.7, 134.1, 129.0, 127.9, 124.3, 121.5, 109.7, 108.6, 60.8
(CH2), 52.9 (2× CH2, piperazine), 43.7 (2× CH2, piperazine);
MS (ESI+, m/z): 322.14 [M + H]+, 1665.19, 158.16. Anal.
Calcd for C18H19N5O: C, 67.27; H, 5.96; N, 21.79. Found: C,
67.41; H, 6.11; N, 21.64.
4.1.14. 5-((4-(3-Fluorophenyl)piperazin-1-yl)methyl)-
quinolin-8-ol (11). (Reaction time: 15 min; 0.279 g, 83%);
Rf = 0.7 (hexane/EtOAct, 1/1); mp 162−3 °C; IR (KBr) ν:
3312, 2936, 2820, 1612, 1579, 1506 cm−1; 1H NMR (400
MHz, CDCl3): δ 8.79 (dd, J = 4.2, 1.5 Hz, 1H), 8.70 (dd, J =
8.5, 1.5 Hz, 1H), 7.47 (dd, J = 8.5, 4.2 Hz, 1H), 7.36 (d, J = 7.7
Hz, 1H), 7.16 (dd, J = 15.3, 8.2 Hz, 1H), 7.09 (d, J = 7.7 Hz,
1H), 6.64 (dd, J = 8.4, 2.3 Hz, 1H), 6.53 (ddt, J = 15.3, 8.2, 2.4
Hz, 2H), 3.85 (s, 2H), 3.20−3.11 (m, 4H), 2.67−2.53 (m,
4H); 13C NMR (101 MHz, CDCl3): δ 165.0, 162.6, 153.0,
152.9, 151.9, 147.6, 138.7, 134.1, 130.1, 130.0, 129.0, 127.9,
124.2, 121.5, 111.1, 111.0, 108.6, 105.8, 105.6, 102.7, 102.4,
60.6 (CH2), 52.8 (2× CH2, piperazine), 48.6 (2× CH2,
piperazine); MS (ESI+, m/z): 338.27 [M + H]+, 181.08,
158.06. Anal. Calcd for C20H20FN3O: C, 71.20; H, 5.98; N,
12.45. Found: C, 71.36; H, 6.02; N, 12.02.
4.2. Biological Evaluation. 4.2.1. Cell Culture and
Transfection. Human embryonic kidney 293T (HEK-293T)
cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate,
100 units/mL penicillin/streptomycin, and 5% (v/v) fetal
bovine serum [all supplements were from Invitrogen, (Paisley,
Scotland, UK)]. Cells were maintained at 37 °C in a
humidified atmosphere of 5% CO2 and were passaged, with
trypsin (Thermo Fisher Scientific, Waltham, MA, USA), when
they were 80−90% confluent, that is, approximately twice a
week. Cells were transiently transfected with the polyethyle-
nimine (Sigma, St. Louis, MO, USA) method as previously
described.31,32 Experiments were carried out in cells expressing
dopamine D2 or D3 receptors.
4.2.2. cAMP Determination and ERK Phosphorylation
Assays. Details of the protocols are provided elsewhere.33,34
For cAMP assays, cells were serum deprived and a
phosphodiesterases inhibitor was used (50 μM zardaverine).
ACS Omega Article
DOI: 10.1021/acsomega.8b02509
ACS Omega 2018, 3, 17368−17375
17373
Agonists were added 15 min before addition of forskolin (0.5
μM) forskolin, and reaction took place for 60 min (25 °C).
The cAMP level was determined using the Lance Ultra cAMP
kit (PerkinElmer, Waltham, MA, USA), and readings were
performed in a PHERAstar (BMG Lab technologies,
Offenburg, GE) equipped with an HTRF optical module.
For pERK1/2 determination, the procedure was similar, but
cells were washed prior use of lysing buffer (20 min 0°−4°).
Supernantants (10 μL) were analyzed using ad hoc
AlphaScreen SureFire and the EnSpire Reader (both from
PerkinElmer, Waltham, MA, USA). When indicated, the
antagonist was added 15 min prior to the addition of the
agonist. The lack of effect (cAMP or pERK1/2 assays) in non-




The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acsome-
ga.8b02509.
Lack of effect of piribedil and compounds 6 or 10 in
cells that do not express dopamine receptors, that is, in
untransfected HEK-293T cells (Figure S1) (PDF)
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M. I.; Alcaro, S.; et al. N-Methyl-N-((1-Methyl-5-(3-(1-(2-
Methylbenzyl)Piperidin-4-Yl)Propoxy)-1H-Indol-2-Yl)Methyl)Prop-
2-Yn-1-Amine, a New Cholinesterase and Monoamine Oxidase Dual
Inhibitor. J. Med. Chem. 2014, 57, 10455−10463.
(25) Gaulton, A.; Hersey, A.; Nowotka, M.; Bento, A. P.; Chambers,
J.; Mendez, D.; Mutowo, P.; Atkinson, F.; Bellis, L. J.; Cibriań-Uhalte,
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